Wounds and Injuries
Conditions
Keywords
Lower extremity
Brief summary
Proportion of postoperative complications (infections, dehiscence, graft slough) after initial application of Integra™
Detailed description
This is a study examining the use of Integra™ for the treatment of lower extremity wounds to better understand the relationship between bacteria contamination levels and post-operative complications. Wounds requiring operative application of Integra™ alone or Integra™ followed by a planned subsequent application of a STSG will be enrolled into this study. The tolerance of Integra™ to bacterial bioburden at the time of application will be determined by observing their respective postoperative wound complications and correlating these findings with quantitative bacterial counts, qualitative culture results, and bacterial and wound protease levels at the time of Integra™ alone application or Integra™ followed by STSG application. Patients will then be followed until complete healing has occurred or until 16 weeks, whichever comes first.
Interventions
DEVICEIntegra™ dermal regeneration template
Integra a biologic dressing for deep wounds or large soft tissue defects that penetrate to the level of bone
Sponsors
Integra LifeSciences Corporation
Georgetown University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Male or Female age 18-90. * Full-thickness wounds below the knee. * Patients who require, in the opinion of the Investigator, operative application of Integra™. * Patients able and willing to comply with the study protocol.
Exclusion criteria
* Male or Female under 18 or over 90 * Patients that do not have Full-thickness wounds below the knee * Patients who do not require, in the opinion of the Investigator, operative application of Integra™. * Patients that are not able or willing to comply with the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine a threshold in which Integra is tolerant to bacteria that yields positive results (healing). The investigators believe that this device is more tolerant to bacterial load then current perception. | 1 year | Quantitative CFUs will be obtained by obtaining tissue from the wound at the time of debridement from otherwise discarded tissue. After tissue cultures are obtained and sent to a designated microbial lab for analysis. Tissue culture is to be obtained from the central aspect of the wound bed. These cultures will be processed and analyzed for research purposes. Qualitative cultures will be obtained as per SOC and sent to the local lab per customary fashion. Qualitative bacterial protease and human inflammation protease indications will be obtained by sampling and testing two separate wound fluid swabs on investigational devices; WOUNDCHEKTM Bacterial Status and WOUNDCHEKTM Protease Status. Bacterial Status detects enzymes that are present when bacteria have become pathogenic while Protease Status detects enzymes present when the wound is in a chronically inflamed state. The tests will be obtained from Woundchek Labs. |
Countries
United States
Contacts
Primary ContactBrittany Spinelli
Outcome results
None listed